{
    "Trade/Device Name(s)": [
        "MammaPrint\u00ae FFPE",
        "MammaPrint FFPE"
    ],
    "Submitter Information": "Agendia Inc.",
    "510(k) Number": "K201902",
    "Predicate Device Reference 510(k) Number(s)": [
        "K141142"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI"
    ],
    "Summary Letter Date": "July 8, 2020",
    "Summary Letter Received Date": "July 8, 2020",
    "Submission Date": "November 3, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "genetic molecular"
    ],
    "Analyte(s)": [],
    "Specimen Type(s)": [
        "Formalin-fixed paraffin embedded (FFPE) breast cancer tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Agilent scanner part #G2505",
        "Agilent SureScan Dx microarray scanner part #G5761AA"
    ],
    "Method(s)/Technology(ies)": [
        "Microarray-based gene expression analysis"
    ],
    "Methodologies": [
        "Gene expression profiling"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Agendia MammaPrint FFPE microarray gene expression profiling system to assess risk of distant breast cancer metastasis.",
    "Indications for Use Summary": "Qualitative in vitro diagnostic test using FFPE breast cancer tissue gene expression to assess risk of distant metastasis within 5 years for Stage I or II, tumor size \u2264 5.0 cm, lymph node negative patients; indicated as a prognostic marker with other clinicopathological factors.",
    "fda_folder": "Immunology"
}